




WOMEN AND FABRY



Fabry disease is an “X-linked” genetic (inherited) disorder. The disease is caused by a change in the DNA called a “mutation.” This mutation happens on the X chromosome, and can be passed down by either a man or a woman. Thousands of women around the world have Fabry disease; however, as recently as 2001, women with the mutation that causes Fabry were considered by medical professionals to be “asymptomatic” carriers of the disease, meaning they could pass on Fabry without actually having any signs or symptoms of the disease.¹ We now know that most women who have the mutation in the gene *do* experience the effects of Fabry,²⁻⁵ often as severely as affected men who have the mutation. Women may first become aware of the effects of Fabry in their teens, but many are not diagnosed for at least 10 years after this first awareness.³ Symptoms may range from mild to moderate to serious and debilitating, and researchers are still studying how Fabry affects women.

This figure shows some of the more common effects of Fabry in women



Women with Fabry may experience all or just some of these effects to different extents, or they might never feel any of them.

Scientists are not completely certain why there is so much variation, but some believe that it has something to do with “X inactivation.” In each cell in a woman’s body, there are two X chromosomes. Randomly during fetal development, one of the two X chromosomes in each cell is inactivated (this could be the normal X chromosome, or the X chromosome with the mutation associated with Fabry). This process is referred to as X inactivation. This random selection of the X chromosome may explain the variation of Fabry symptoms in women.³ That is, the number of normal cells that are inactivated vs cells with the mutation can affect organ involvement and the severity of a woman’s experience of Fabry. Regardless of the experience of each woman with Fabry, all women with the disease should speak with their healthcare provider (HCP) about regular monitoring, since there can be significant effects of the disease.⁵



More than medical

In addition to physical signs and symptoms of the disease, many women living with Fabry have decreased quality of life.^{4,5}



In one study where researchers looked at responses of women with Fabry and women without Fabry to a health-related quality-of-life survey, they found that pain was associated with lower mood and less enjoyment of life. Many women had poorer impressions of their own vitality, social functioning, and overall mental health than women who did not have Fabry. In this study, researchers found depression in almost two-thirds of women with Fabry and anxiety in more than one-third.⁵



Another study, in which 202 women with Fabry completed questionnaires to determine their quality of life, researchers found that women with Fabry had a self-reported quality of life similar to, and sometimes even worse than, that of people with multiple sclerosis (MS) and rheumatoid arthritis (RA)—other chronic diseases commonly understood to have a major impact on people’s lives.⁴



Of course, we cannot forget that women don’t just have to think of themselves and how they are doing or feeling. Many women have multiple roles: they may be working, managing a home, and caring for others with Fabry, including children, siblings, and/or parents. This can be overwhelming for anyone! Finally, we also know that people with Fabry may have feelings of isolation, fear, and guilt for having and possibly passing the disease on to their children.

Despite having all of these physical and psychological effects, some women still find that not all HCPs believe their experiences are serious.⁶ Even though researchers agree that women are not “just carriers,” as people used to believe, some providers still need to be convinced. This can cause serious frustration and even mistrust of doctors or other HCPs among women with Fabry.^{6,7}

All of these things together—the physical, emotional, and social effects of Fabry—could make it difficult for women to find the time and the energy to take care of themselves and focus on their own health and well-being. It is this combined impact that is exactly what makes it so important. If women with Fabry are to live the best lives possible and continue to support those who count on them, they must make the time to recognize and address their own needs.

Women who live with Fabry face unique challenges. As understanding of Fabry continues to grow, it is helpful to learn as much as possible and know that many other women share similar experiences. To find out more about Fabry disease and the Fabry community, the links available at http://amicusrx.com/external_resources.php may be useful.

REFERENCES: 1. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. *J Med Genet.* 2001;38(11):769-807. 2. Bouwman MG, Rombach SM, Schenck E, et al. Prevalence of symptoms in female Fabry disease patients: a case-control survey. *J Inher Metab Dis.* 2012;35(5):891-898. 3. Deegan PB, Böhner F, Barba M, Hughes DA, Beck M. Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G, eds. *Fabry Disease: Perspectives From 5 Years of FOS.* Oxford, UK: Oxford PharmaGenesis; 2006. 4. Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. *Genet Med.* 2006;8(6):346-353. 5. Wang RY, Lellis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. *Genet Med.* 2007;9(1):34-45. 6. Gibas AL, Klatt R, Johnson J, Clarke JT, Katz J. Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease. *J Genet Couns.* 2008;17(6):528-537. 7. Gibas AL, Klatt R, Johnson J, Clarke JTR, Katz J. A survey of the pain experienced by males and females with Fabry disease. *Pain Res Manage.* 2006;11(3):185-192.